Sanofi - American Depositary Shares (NQ:SNY)

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

October 01, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

52-Week Range 24.9% below 52-week high

39.54

39.1852W Low 52.6852W High

1 Week 1.9% below 1-week high

39.231W Low 40.311W High

Sanofi - American Depositary Shares (SNY) traded between $39.18 and $52.68 over the past 52 weeks and last traded at $39.54, 24.9% below its 52-week high. Over the past week it ranged between $39.23 and $40.31.

Past 12 Months

-0.1%

-8.7%

-10.1%

-15.8%

-18.0%

-19.0%

1W -$0.02

1M -$3.79

3M -$4.46

6M -$7.42

YTD -$8.69

1Y -$9.26

SNY was -19.0% over the past year, -15.8% over six months, -18.0% year to date, -0.1% in the last week.

12 Months vs Market

SNY

-19.0%

DIA

+12.1%

SPY

+17.1%

QQQ

+23.0%

IWM

+12.9%

Over the past 12 months SNY returned -19.0% versus DIA (Dow) +12.1%, SPY (S&P 500) +17.1%, QQQ (Nasdaq 100) +23.0% and IWM (Russell 2000) +12.9%.

Volume & Liquidity 0.48× 3-mo avg

Today 1,385,031 3-mo avg 2.9M

2.6M

3.1M

2.9M

3.0M

YTD

3.4M

3.2M

SNY most recently traded 1,385,031 shares against a 3-month average daily volume of 2.9M.

More News

Is Regeneron Stock a Bargain Below $800? ↗

September 22, 2026

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine ↗

September 22, 2026

Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability ↗

August 27, 2026

Via Chartmill

Sanofi (NASDAQ:SNY) Screens as Undervalued Value Stock with Solid Profitability ↗

August 07, 2026

Via Chartmill

Sanofi-ADR (NASDAQ:SNY) Offers a High Dividend Yield With Strong Underlying Quality ↗

July 16, 2026

Via Chartmill

Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss ↗

September 20, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile ↗

July 13, 2026

Via Chartmill

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire

Via GlobeNewswire

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity? ↗

August 26, 2026

Sanofi Q2 Earnings Call Highlights ↗

July 30, 2026

The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.) ↗

July 28, 2026

Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

July 21, 2026

Via FinancialNewsMedia

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗

July 08, 2026

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows ↗

June 30, 2026

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

June 22, 2026

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

June 22, 2026